| 1.21 -0.19 (-13.57%) | 08-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.57 |
1-year : | 1.75 |
| Resists | First : | 1.35 |
Second : | 1.5 |
| Pivot price | 1.35 |
|||
| Supports | First : | 1.11 |
Second : | 0.92 |
| MAs | MA(5) : | 1.38 |
MA(20) : | 1.34 |
| MA(100) : | 0.99  |
MA(250) : | 0.99 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 59.7 |
D(3) : | 73.1 |
| RSI | RSI(14): 43.2 |
|||
| 52-week | High : | 1.57 | Low : | 0.4 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TLPH ] has closed below the lower bollinger band by 1.0%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ TLPH ] is to continue within current trading range. Bollinger Bands are 15.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.36 - 1.37 | 1.37 - 1.38 |
| Low: | 1.09 - 1.1 | 1.1 - 1.11 |
| Close: | 1.2 - 1.21 | 1.21 - 1.22 |
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits. The company's development pipeline also features LTX-608, a potential anti-inflammatory and antiviral agent being explored for the treatment of numerous conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, Talphera is advancing Fedsyra, a pre-filled syringe containing ephedrine, and PFS-02, a pre-filled syringe containing phenylephrine. Established in 2005, the company was previously known as AcelRx Pharmaceuticals, Inc. It adopted the name Talphera, Inc. in January 2024 and maintains its corporate headquarters in San Mateo, California.
Thu, 13 Aug 2026
Talphera (TLPH) Advances NEPHRO CRRT Enrollment Amid Guideline S - GuruFocus
Thu, 13 Aug 2026
Talphera Inc (TLPH) (Q2 2026) Earnings Call Highlights: NEPHRO S - GuruFocus
Wed, 12 Aug 2026
Talphera Q2 Earnings Call Highlights - TradingView
Wed, 12 Aug 2026
Talphera (TLPH): Rosalind entities report 9.9% beneficial ownership cap - Stock Titan
Sat, 08 Aug 2026
Talphera (NASDAQ:TLPH) Upgraded at Wall Street Zen - MarketBeat
Fri, 07 Aug 2026
Talphera Inc (TLPH) Stock News Today - tradingkey.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | -6 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 5.19e+007 (%) |
| Held by Institutions | 2.698e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -726000 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.29 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 451 % |
| Return on Equity (ttm) | 600 % |
| Qtrly Rev. Growth | -118.4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -204.9 |
| EBITDA (p.s.) | -389286 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -4.33 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0 |
| Dividend | 881360 |
| Forward Dividend | 667970 |
| Dividend Yield | 72839700% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|